When Will Generic Ozempic Be Available?
Ozempic patent landscape, semaglutide generic timeline, and what it means for GLP-1 drug prices.
Read article →Updated April 2026 · USPTO + FDA Orange Book
PatentCliff Blog
Analysis of patent portfolios, drug expirations, and the patent cliff — every claim grounded in U.S. Patent and Trademark Office records and the FDA Orange Book.
What This Blog Covers
The articles below answer the questions readers most often bring to USPTO patent search and the FDA Orange Book: when a specific drug goes generic, how much prices fall after a cliff, which pharma companies are most exposed in the next earnings cycle, and how to look up exclusivity timing for any approved drug. Each post pulls its data directly from federal sources and links to the underlying entity profiles on this site so readers can drill in.
We focus on three audiences: investors tracking pharma earnings exposure, prescribers and patients waiting for a generic option, and IP professionals tracking Paragraph IV calendars. The voice is plain English; the underlying numbers are pulled from USPTO PatentsView and Orange Book listings.
Latest Articles
Patent Cliff 2026: Every Drug Losing Protection This Year
The full list of drugs losing patent protection in 2026, $45-55 billion in revenue at risk.
Read article →How Much Do Drug Prices Drop After Patent Expiration?
Concrete price data: generics cut costs 80-90%. Historical examples from Lipitor to Humira.
Read article →Which Pharma Stocks Face the Biggest Patent Cliff?
Investor analysis of pharma companies most exposed to upcoming patent expirations.
Read article →Biggest Patent Cliffs in Pharmaceutical History
From the 2011 Lipitor cliff to the 2026 mega-cliff, a timeline of the industry's biggest revenue shocks.
Read article →How to Look Up When Any Drug Patent Expires
Four free and paid tools to check drug patent expiration dates, including the FDA Orange Book.
Read article →Drug Patent Expirations 2026-2030: The Patent Cliff
A timeline of major drug patent expirations with revenue impact estimates, billions in revenue at risk.
Read article →Companies With the Strongest Patent Portfolios
Top companies ranked by Patent Strength Score, portfolio size, claims breadth, and technology diversity.
Read article →What Happens When a Patent Expires? Effects Explained
What happens to drug prices, generic competition, and innovation when patents expire, with real examples.
Read article →How These Articles Are Researched
Every drug-specific article begins with a fresh pull from the FDA Orange Book to confirm currently listed patents, exclusivity periods, and any Paragraph IV-related stays. Patent term math is then computed from USPTO records using a 20-year-from-earliest-non-provisional-filing baseline, with PTA and PTE adjustments where applicable. Revenue figures cited in the cliff articles come from manufacturer 10-K filings and are clearly labeled as such — we do not estimate revenue.
For broader analysis like "biggest cliffs in history," we cross-reference industry coverage with the underlying USPTO and Orange Book records to ensure each number is traceable. Read the full methodology for the data pipeline and limitations.
Frequently Asked Questions
How does PatentCliff cover the pharmaceutical patent cliff?
Every blog post on this site is built on top of two public-domain federal datasets: USPTO patent records (filing dates, expiration dates, assignee, claims, CPC classification) and FDA Orange Book listings (approved drug products and their listed patents and exclusivities). Articles describing a specific drug or company are linked directly to the underlying entity profile pages, where the source data and Patent Strength Score are visible. We do not estimate or model expiration dates — every date in our data comes from a federal record.
Why do drug prices drop so sharply after a patent expires?
Once a brand-name drug loses exclusivity, generic manufacturers can apply for FDA approval through the Abbreviated New Drug Application (ANDA) pathway, which lets them rely on the brand's existing safety and efficacy data instead of running new trials. With multiple generics typically launching within 12 to 18 months, list prices fall 80–95% on small-molecule drugs. The first ANDA filer also gets 180 days of exclusive generic-market access, which compresses the price decline into a fast curve. Biologic drugs (biosimilars) follow a slower curve — typically 30–50% price reductions over multiple years.
What is the "patent cliff" in pharmaceutical terms?
The patent cliff is the cluster of revenue declines that hits a pharmaceutical company — or the industry as a whole — when several major branded products lose patent protection within a short window. The 2011–2013 cliff that included Lipitor, Plavix, Singulair, and others wiped roughly $100 billion in annual branded revenue off the industry over three years. The 2026–2030 window contains another large cluster, anchored by biologics like Stelara and Xtandi alongside small-molecule blockbusters like Eliquis. The articles in this section quantify each upcoming cliff using USPTO and Orange Book filings.
How are patent expiration dates calculated?
A standard U.S. utility patent expires 20 years from its earliest non-provisional filing date. We compute that base term from USPTO patent records, then layer in any Patent Term Adjustment (granted to compensate for USPTO processing delays) and Patent Term Extension (granted under the Hatch-Waxman Act for time lost during FDA review). For drugs specifically, we cross-check against Orange Book listed patents, which include both compound patents and method-of-use patents that may have different expiration dates. The earliest unblocking event — patent expiry or exclusivity loss — is what enables generic entry.
How can readers verify the data behind these articles?
Every drug or company referenced in an article links to its profile page on this site, which lists the underlying patents with USPTO patent numbers. Readers can verify any patent independently using the USPTO Patent Public Search system (ppubs.uspto.gov), Google Patents, or the FDA Orange Book for drug-specific exclusivities. We treat these federal sources as authoritative; if our records differ from a fresh USPTO query, the USPTO record is correct.
Sources: U.S. Patent and Trademark Office (PatentsView, Open Data Portal); U.S. Food and Drug Administration (Orange Book). Public-domain federal data. Cite as: "PatentCliff. Data: USPTO + FDA Orange Book."
Last updated 2026-04-10.